Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFB2 | P61812 | 1/20 | 0.51 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 6/20 | 0.37 |
| ▸ | CDC7 | O00311 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
| ▸ | IKBKB | O14920 | 4/20 | 0.36 |
| ▸ | CHUK | O15111 | 4/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18155078 | 0.88 | TGFB2 (0.52) | TGFB2PIM1CDC7CDK9PIM3 | |
| SCHEMBL20048367 | 0.85 | TGFB2 (0.55) | TGFB2PIM1PIM3ACVR1PDGFRB | |
| SCHEMBL18155028 | 0.85 | TGFB2 (0.49) | TGFB2PIK3C3PIM1PIM3PIM2 | |
| SCHEMBL18155048 | 0.84 | TGFB2 (0.51) | TGFB2PIM1CDC7CDK9PIM3 | |
| SCHEMBL18155106 | 0.81 | TGFB2 (0.52) | TGFB2PIM1CDC7PIM3PIM2 | |
| SCHEMBL18164058 | 0.81 | BMPR1B (0.45) | TGFB2ACVR1PDGFRBFGFR1KDR | |
| SCHEMBL18155031 | 0.80 | RHEB (0.46) | TGFB2PIK3C3IKBKBCHUK | |
| SCHEMBL18155101 | 0.80 | PIK3C3 (0.41) | TGFB2PIK3C3PIM1CDC7CDK9 | |
| SCHEMBL18164050 | 0.79 | TGFB2 (0.58) | TGFB2PIM1CDK9PIM3PIM2 | |
| SCHEMBL18163943 | 0.79 | TGFB2 (0.57) | TGFB2PIM1CDK9PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283475-B1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-10-16 | — | — | EP | claimed |
| EP-3283475-A1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | Merck Patent GmbH (DE) | 2018-02-21 | — | — | EP | claimed |
| WO-2016165808-A1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-10-20 | — | — | WO | claimed |
| EP-3283475-B1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-10-16 | — | — | EP | disclosed |
| US-10179777-B2 | 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives | MERCK PATENT GMBH (DE) | 2019-01-15 | — | — | US | disclosed |
| US-20180099947-A1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179777-B2 | 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives | ALK, ABL2, ACVR1 | TGFB2 267/4885PIK3C3 2641/4885PIM1 68/4885 |
| US-20180099947-A1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | ALK, ABL2, ACVR1 | TGFB2 267/4885PIK3C3 2641/4885PIM1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.